Bruno Montanari
Director/Board Member chez BIOTECH ACQUISITION COMPANY
Profil
Bruno Montanari is a Partner at Seroba.
He has a background in venture capital and in investment banking, with a focus on the pharmaceutical, biotechnology and medical device industries.
Bruno graduated in 1998 with a PharmD.
from the Université René Descartes, Paris V and in the same year completed a Master’s degree in Strategic Management at HEC.
Prior to joining the firm in 2017, Bruno was a Partner at Omnes Capital (Paris) in charge of life sciences investments for the venture capital team.
His previous venture capital experience was at Atlas Venture (Paris/London) and CDP Capital (Paris/Montreal).
He started his career in 1999 in London, in the healthcare teams of the investment banking divisions of Deutsche Bank and later Merrill Lynch.
Bruno brings a wealth of experience and network, particularly in continental Europe, where he is based.
Bruno sits on the boards of Coave Therapeutics, STORM Therapeutics and Sibylla Biotech.
Postes actifs de Bruno Montanari
| Sociétés | Poste | Début |
|---|---|---|
| BIOTECH ACQUISITION COMPANY | Director/Board Member | 25/01/2021 |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Director/Board Member | - |
Seroba BioVentures Ltd.
 Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | Private Equity Investor | 01/12/2017 |
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Director/Board Member | - |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Director/Board Member | 28/06/2011 |
Anciens postes connus de Bruno Montanari
| Sociétés | Poste | Fin |
|---|---|---|
Omnes Capital SAS /Venture/
 Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Private Equity Investor | 31/12/2017 |
Xention Ltd.
 Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The private company is based in Newmarket, UK. Xention was founded in 2002. | Director/Board Member | 30/06/2016 |
| ARGENX SE | Director/Board Member | 13/05/2015 |
| Atlas Venture SARL | Private Equity Investor | 01/02/2009 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Bruno Montanari
| École des Hautes Études Commerciales de Paris | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| POXEL | Health Technology |
| ARGENX SE | Health Technology |
| Entreprise privées | 27 |
|---|---|
Merrill Lynch International
 Merrill Lynch International Investment Banks/BrokersFinance Merrill Lynch International (MLI-UK) is a brokerage firm headquartered in London, UK. The firm was founded in 1988 and is a subsidiary of ML UK Capital Holdings Ltd., ultimately owned by Bank of America Corp. (NYSE: BAC) in the US. MLI-UK provides brokerage services to individual and retail clients. | Finance |
Cellzome Ltd.
 Cellzome Ltd. Pharmaceuticals: MajorHealth Technology Cellzome Ltd. engages in the research, development, and manufacture of pharmaceutical products. It provides kinase-targeted drugs to treat inflammatory diseases. The company was founded by Gitte Neubauer on December 22, 2003 and is headquartered in Middlesex, the United Kingdom. | Health Technology |
Xytis, Inc.
 Xytis, Inc. BiotechnologyHealth Technology Xytis, Inc. was engaged in the development of central nervous system. The company was founded by Werner Tschollar in January 2006 and was headquartered in Irvine, CA. | Health Technology |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Health Technology |
Novexel SA
 Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Health Technology |
Cytheris SA
 Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Health Technology |
CDP Capital-Financing, Inc.
 CDP Capital-Financing, Inc. Financial ConglomeratesFinance CDP Capital-Financing, Inc. provides financing and investment services. The private company is based in Montréal, Canada. The Canadian company is ultimately controlled by the Province of Québec. | Finance |
Omnes Capital SAS /Venture/
Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Finance |
| Atlas Venture SARL | Finance |
Novate Medical Ltd.
 Novate Medical Ltd. Medical SpecialtiesHealth Technology Novate Medical Ltd. operates as a medical device company which focuses on the prevention of pulmonary embolism in venous thromboembolic events. Its product Sentry, bioconvertible inferior vena cava (IVC) filter for the prevention of pulmonary embolism (PE) in patients at transient PE risk. The company was founded by Charles Richard Taylor and Paul Burke Gilson in 2006 and is headquartered in Dublin, Ireland. | Health Technology |
EOS Imaging SA
 EOS Imaging SA Medical SpecialtiesHealth Technology EOS Imaging SA engages in the development and marketing of imaging and imaged-based solutions for diagnosing, treating, and monitoring common musculoskeletal pathologies. It operates through the France and North America geographical segments. The firm trademarks include EOSedge, sterEOS, spineEOS, hipEOS, and kneeEOS. The company was founded by Georges Charpak on February 8, 1989 and is headquartered in Paris, France. | Health Technology |
Eye Tech Care SA
 Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | Health Technology |
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Health Technology |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Health Services |
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Health Technology |
| Université de Paris 5 René Descartes | Consumer Services |
Deutsche Bank AG (London Branch)
 Deutsche Bank AG (London Branch) Regional BanksFinance Deutsche Bank AG provides corporate banking and investment services. It offers asset and wealth management, corporate banking and securities and global transaction banking solutions. The company was founded in 1873 and is headquartered in London, the United Kingdom. | Finance |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The private company is based in Newmarket, UK. Xention was founded in 2002. | Health Technology |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | Finance |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Tissium SA
 Tissium SA BiotechnologyHealth Technology Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France. | Health Technology |
Ophthakem NV
 Ophthakem NV BiotechnologyHealth Technology Ophthakem NV is a Belgian company that conducts research in the field of biotechnology. The company is based in Diepenbeek, Belgium and was founded in 2013. | Health Technology |
STORM Therapeutics Ltd.
 STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Health Technology |
| Newron Pharmaceuticals US, Inc. | |
Biotech Acquisition Co.
 Biotech Acquisition Co. Financial ConglomeratesFinance Biotech Acquisition Co. is a blank check company, which engages in the effectuation of a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one business. The company was founded on September 3, 2020 and is headquartered in New York, NY. | Finance |
